Furthermore, thymidine kinase inhibitor (TKI)-resistant leukemic stem cells (LSCs) in CML are maintained in the bone marrow in a CXCL12-dependent manner, indicating that loss of CXCL12 inhibits maintenance of LSC quiescence and makes them sensitive to TKIs [67]. The gene discussed is CXCL12; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.